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Background: Caloric restriction and n-3 polyunsaturated fatty acid (PUFA) supplementation protect from some of
the metabolic complications. The aim of this study was to assess the influence of a low calorie diet with or with-
out n-3 PUFA supplementation on glucose dependent insulinotropic polypeptide (GIP) output and insulin sensi-
tivity markers in obese subjects.
Methods: Obese, non-diabetic subjects (BMI 30–40 kg/m2) and aged 25–65 yr. were put on low calorie diet (1200–
1500 kcal/day) supplemented with either 1.8 g/day n-3 PUFA (DHA/EPA, 5:1) (n= 24) or placebo capsules (n=
24) for three months in a randomized placebo controlled trial. Insulin resistance markers and GIP levels were
analysed from samples obtained at fasting and during an oral glucose tolerance test (OGTT).
Results: Caloric restriction with n-3 PUFA led to a decrease of insulin resistance index (HOMA-IR) and a significant
reduction of insulin output as well as decreased GIP secretion during the OGTT. These effects were not seen with
caloric restriction alone. Changes inGIP outputwere inversely associatedwith changes in red blood cell EPA content
whereas fasting GIP level positively correlatedwith HOMA-IR index. Blood triglyceride level was lowered by caloric
restriction with a greater effect when n-3 PUFA were included and correlated positively with fasting GIP level.
Conclusions: Three months of caloric restriction with DHA + EPA supplementation exerts beneficial effects on
insulin resistance, GIP and triglycerides.
General significance: Combining caloric restriction and n-3 PUFA improves insulin sensitivity, which may be related
to a decrease of GIP levels.
© 2015 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Obesity and its associated disorders (impaired insulin sensitivity,
hyperinsulinemia, dyslipidemia, hypertension) often lead to type 2 dia-
betes with increased risk for cardiovascular disease [1–3]. Obesitys index; DHA, docosahexaenoic
insulinotropic polypeptide; IGI,
, oral glucose insulin sensitivity
choline; PUFA, polyunsaturated
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pen access article under the CC BY-Ncontributes to type 2 diabetes development by affecting glucose and
lipid homeostasis,which depends on the balance between insulin sensi-
tivity and insulin secretion [4]. Incretins account for 50–70% of insulin
secretion after meals or an oral glucose load [5]. Glucose-dependent
insulinotropic polypeptide (GIP) is released from enteroendocrine K
cells in response to oral ingestion of fat or glucose [6] and stimulates in-
sulin secretion from pancreatic β-cells in a glucose-dependent manner
[7]. Transduction of its biological effects involves stimulation of G
protein-coupled receptors (GPCR) [8], for example GPR 120 [9].
Adequate insulin sensitivity and insulin secretion can be restored by
achieving appropriate bodymass through adopting a healthy diet, ener-
gy restriction, and physical activity [10–11]. A diet rich in omega-3 (n-3)
polyunsaturated fatty acids (PUFA) reduces risk for obesity complica-
tions by influencing lipid metabolism, inflammation, coagulation andC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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changes in cell membrane phospholipid fatty acid composition, which
affects cell and tissue function through alterations in the properties of
membranes, altered cell signalling pathways, and modified gene ex-
pression profiles [15–18]. Docosahexaenoic acid (DHA, 22:6n-3) and
eicosapentaenoic acid (EPA, 20:5n-3) are considered the most biologi-
cally active n-3 PUFA [19–20].
Beneficial effects of n-3 PUFA on glucose homeostasis have been
documented in animal models of obesity and metabolic syndrome
[21–22]. Improvement in glucose tolerance after n-3 PUFA supplemen-
tation in obese humans has been less frequently reported and seems to
be related to the presence of obesity complications [23–26]. Whether
GIP is involved in the effect of n-3 PUFA on the insulin response to a
glucose load has not been reported in human studies. Thus, it is not
clear if n-3 PUFA affect the incretin system in humans with obesity
and prediabetes.
The aim of this study was to investigate the effects of caloric restric-
tionwith or without consumption of n-3 PUFA (DHA+EPA) on GIP, in-
sulin release and metabolic variables at fasting and during an OGTT in
obese, non-diabetic subjects.
2. Materials and methods
2.1. Subjects
Obese subjects (BMI 30–40 kg/m2) aged 25–65 years were recruited
from the Out-Patient Clinic of Obesity and Lipid Disorders and the De-
partment of Metabolic Disorders, Jagiellonian University Medical Col-
lege, Krakow, Poland. Exclusion criteria included: diabetes or other
endocrine disorders, chronic inflammatory diseases, and kidney or
liver dysfunction. Subjects participating in the study had not taken
lipid-lowering or anti-inflammatory drugs or supplements containing
vitamins A, C, or E, β-carotene or PUFA. Fish consumption was not
allowed during the study period.
2.2. Study design and intervention
This clinical trial was randomized, double-blind placebo-controlled
parallel and single center. The trial was carried out in accordance with
The Code of Ethics of theWorld Medical Association (Declaration of Hel-
sinki) and with the Good Clinical Practise guidelines. The trial was ap-
proved by Bioethics Committee of the Jagiellonian University in Cracow
(written consent, opinion No. KBET/82/B/2009) and all subjects gave
written informed consent. The trial was conducted at the Department
of Clinical Biochemistry, JagiellonianUniversity,Medical College, Krakow,
Poland. The trial was registered at isrctn.com as ISRCTN11445521.
Recruited subjects were randomly assigned to the n-3 PUFA or the
placebo groupbyusingminimalization software balanced for age and sex.
Obese subjects (BMI 30–40 kg/m2) underwent an adaptation period
of two weeks. During this time they were advised by a dietician on how
to apply an isocaloric diet containing 2300–2400 kcal/d according to in-
dividual caloric requirement. The diet contained 57% of energy from car-
bohydrates, 30% from fat and 13% from protein. After the adaptation
period, subjects were advised to use a low calorie diet. The caloric
value of the low calorie diet was 1200 kcal/d for women and
1500 kcal/d for men and 60% of energy was provided from carbohy-
drates (with low glycemic index), 15% from protein and 25% from fat.
Subjects were randomly assigned to receive placebo (corn oil) capsules
(CR placebo) or n-3 PUFA (EPAX 1050TG; EPAX, Norway) capsules
(CR + n-3). Subjects consumed 3 capsules per day for 3 months.
Three n-3 PUFA capsules contained 1.8 g DHA + EPA in a ratio of 5:1.
Both capsule types were identical in size, shape and appearance and
contained 4mg of vitamin E per capsule. Subjects were advised to swal-
low their capsules after a meal.
All subjects were givenwritten and verbal instructions by a dietician
about the preparation of a caloric restricted diet and consumption ofcapsules. Body composition changes including fat content, muscle
mass and water content were measured by Tanita Body Composition
Analyser BC-418 (Tanita, Japan). Hip and waist circumferences, diet
and supplementation compliance, and nutritional habits were assessed.
Anthropometric measurements (BMI, hip and waist circumference,
systolic and diastolic blood pressure, adipose tissue content) were per-
formed at baseline (after the two week adaptation period) and at the
end of three months intervention and after a 12 h overnight fast. An
oral glucose tolerance test (OGTT; 75 g glucose load)was performed ac-
cording to WHO guidelines. At fasting and every 30 min up to 2 h ve-
nous blood was collected for measurement of serum glucose, insulin,
GIP, non-esterified fatty acids (NEFA), total cholesterol, HDL cholesterol
and triglycerides. Additionally, at fasting baseline and at the end of
treatment venous blood was collected for determination of plasma
phosphatidylcholine (PC) composition and fatty acid content of eryth-
rocytes’ membranes (see below). All samples were centrifuged at
1000 x g for 15 min at 4 °C. Serum, plasma and erythrocytes’ samples
were aliquoted and stored at−80 °C until analysis. Sample sizewas cal-
culated to 25 per group to detect a 50% change in insulin sensitivity
markers at a P value b0.05 with a power of 80%.
2.3. Compliance
Counting the number of returned capsules during the follow up
visits was used to assess compliance to capsules intake. In addition,
the fatty acid composition of plasma phosphatidylcholine (PC), and of
erythrocytes (RBC) was determined by gas chromatography using
methods described previously [27].
Because of concerns about compliance to n-3 PUFA capsules in the n-
3 PUFA group and contamination in the placebo group (i.e. intake of n-3
PUFA capsules) it was decided before hand to use a cut-off of a 20% in-
crease in “omega-3 index”, the sum of EPA + DHA in erythrocytes, to
identify compliers in the n-3 PUFA group and violators in the placebo
group. Using the threshold of a 20% increase in omega-3 index resulted
in retention of data for 24 subjects in the n-3 PUFA group and 24 sub-
jects in the placebo group.
2.4. Biochemical measurements
Subjects were instructed to avoid strenuous exercise and alcohol
consumption the day before blood collection. Plasma glucose, total
cholesterol, HDL-cholesterol and triglycerides were assayed by auto-
mated, enzymatic colorimetric methods (ELITech Clinical Systems,
France). The intra and inter-assay variability coefficients were as fol-
lows: 2.3% and 3.5% (glucose), 1.4% and 3.4% (triglycerides), 1.4% and
3.8% (total cholesterol), 2.1% and 2.8% (HDL-cholesterol), respective-
ly. LDL-cholesterol was calculated from measured values of total
cholesterol, triglycerides and HDL-cholesterol according to the
Friedewald formula.
Non esterified fatty acids (NEFA) concentration was measured im-
mediately in non-frozen plasma by enzymatic quantitative colorimetric
method (Roche Diagnostics GmbH, Germany).
Insulin was determined by an immunoradiometric method
(DIAsource ImmunoAssays, Belgium) and read using a gamma counter
(LKB Instruments).Within and between-run imprecision CVswere 2.1%
and 6.5%, respectively.
GIP was measured using ELISA (EMD Millipore, St. Charles, MO,
USA). Within-run CV was 6.1% and between-run CV 8.8%. The limit of
detection was 8.2 pg./ml.
2.5. Presentation of results
Area under concentration time curve (AUC) for glucose, insulin, GIP,
triglycerides and NEFA during the OGTT was calculated by the trapezoi-
dal method [28]. Β-cell function was assessed by the ratio of the insulin
to glucose AUC (AUCI/AUCG) and the insulinogenic index (IGI). IGI is a
9U. Razny et al. / BBA Clinical 4 (2015) 7–13measure of first-phase insulin secretion [29] and was calculated as the
ratio of the difference between the post oral glucose load insulin peak
(at 60 min) and basal insulin to the difference in glucose levels (IGI =
ΔI0-60/ΔG0-60). Basal insulin resistance was estimated using homeosta-
sis model assessment (HOMA-IR) [30]. Post oral glucose load insulin
sensitivity was determined using an oral glucose insulin sensitivity
index (OGIS) proposed by Mari et al. [31] which can be computed
using a calculator for Excel spread sheet available on the webpage
http://webmet.pd.cnr.it/ogis.2.6. Statistical analysis
Only responders were included in the analysis (n = 24 in the n-3
PUFA group and n = 24 in the placebo group). The Kolmogorov-
Smirnov test was used to test the data for a Gaussian distribution.
Normally distributed data are presented as mean ± SEM, otherwise
as median and interquartile range (IQR). Between group differences
were analysed by unpaired t test or non-parametric U-Mann Whit-
ney test. Continuous variables obtained before and after the treat-
ment were log transformed if required and analysed by paired t
test (non-normally distributed data were analysed by Wilcoxon's
test) to identify treatment-induced differences between individual
groups. Spearman rank correlation was used to assess relationship
between variables. All analyses were performed with Statistica
software (StatSoft). A P value b0.05 was considered statistically
significant.Fig. 1. CONSORT fl3. Results
3.1. Study population, intervention and basal characteristics of subjects
This trial aimed to investigate the effect of n-3 PUFA supplementa-
tion on insulin sensitivity markers in obese nondiabetic subjects on a
calorie restricted diet. The recruitment of obese study participants
began in September 2009 and was completed in July 2013.
Eighty-five of 195 screened obese subjects were enrolled in the
study and randomly assigned to n-3 PUFA or placebo treatment. The
progression of subjects through the study is shown in Fig. 1. Three sub-
jects were lost to follow-up (2 in the n-3 PUFA group and 1 in the place-
bo group). After randomization, 2 subjectswere excluded (1 from then-
3 PUFA group and 1 from the placebo group) because they were newly
diagnosed with type 2 diabetes during the 2-h OGTT. Six subjects de-
clined to participate after allocation to intervention groups: one from
the placebo group due to family problems and five from the n-3 PUFA
group (reasons not known). Six subjects were excluded during the
follow-up period. Three subjects from the placebo group discontinued
intervention: 1 woman due to pregnancy and 2 subjects got new work
outside the country. From the n-3 PUFA group 3 subjects were exclud-
ed: one subject claimed that taking capsules leads toweight gain, 1 sub-
ject developed pneumonia that required hospitalization and 1 subject
required hospitalization for decompensation of preexisting heart fail-
ure. The n-3 PUFA capsules were safe and well tolerated. No adverse ef-
fects were observed after DHA/EPA (5:1) supplementation except one
subject who claimed that taking these capsules contributes to weightow diagram.
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group completed the trial. Twenty subjectswere excluded from analysis
due to not meeting compliance criteria: 12 subjects from the placebo
group (omega-3 index after supplementation increased more than
20%) and 8 subjects from the n-3 PUFA group (increase in omega-3
index was less than 20% after supplementation). Thus, full analyses
were performed in 48 subjects: 24 in the placebo group and 24 in the
n-3 PUFA group. Baseline characteristics did not differ between CR pla-
cebo and n-3 PUFA (CR + n-3) groups (Table 1). Subjects were mainly
women (approximately 80%) with a mean age of 48 years, moderately
obese (BMI: 34.7 ± 0.5 kg/m2) and without hypertension. The low
value of baseline omega-3 fatty acid index (5.63 ± 0.19%) is consistent
with the selection of subjects with low fish intake. Subjects had slightly
elevated total and LDL cholesterol concentrations although plasma
triglyceride concentrations were not elevated (Table 1). Fasting blood
glucose concentration was normal but plasma insulin concentration
was slightly increased (Table 1).
3.2. Anthropometric measurements and lipid parameters after intervention
After the 3 month intervention period, subjects in the CR + n-3
group had higher levels of EPA and DHA in plasma phosphatidylcholine
(PC) (average 55% and 80% increase over baseline, respectively) and in
erythrocytes (average 80% and 63% increase over baseline, respectively),
as well as mean 66% increase in the omega-3 index compared to base-
line (9.01 ± 0.36 vs. 5.41 ± 0.25%; P b 0.0001) (Table 2). In the CR pla-
cebo group the level of n-3 PUFA in RBC and omega-3 index did not
change, although a decrease in plasma PC EPA, but not DHA, was ob-
served (P = 0.02).Table 1
Baseline characteristics of the obese subjects included in the analysis.
All subjects (n = 48) P
Age [y] 47 ± 22 4
Sex, female [n] 38 2
EPA in plasma PC [weight%] 2.22 ± 0.22 2
DHA in plasma PC [weight%] 3.68 ± 0.22 3
EPA in RBC membranes [%] 1.12 ± 0.06 1
DHA in RBC membranes [%] 4.51 ± 0.15 4
Omega-3 index [%] 5.63 ± 0.19 5
Anthropometric measurements:
Weight [kg] 96.18 ± 1.67 9
BMI [kg/m2] 34.75 ± 0.51 3
Waist to hip ratio 0.85 (0.82, 0.93)3 0
Adipose tissue mass [%] 39.68 ± 0.91 4
Systolic BP [mm Hg] 128.40 ± 2.49 1
Diastolic BP [mm Hg] 84.30 ± 1.39 8
Metabolic measurements:
Total cholesterol [mmol/l] 5.51 ± 0.16 5
HDL cholesterol [mmol/l] 1.31 ± 0.04 1
LDL cholesterol [mmol/l] 3.53 ± 0.13 3
Fasting NEFA [mmol/l] 0.77 ± 0.04 0
AUC NEFA [mmol/l x min−1] 166.59 ± 11.15 1
Fasting Triglycerides [mmol/l] 1.38 ± 0.09 1
AUC Triglycerides [mmol/l x min−1] 641.75 ± 43.63 6
Fasting glucose [mmol/l] 5.15 ± 0.09 5
AUC Glucose [mmol/l x min−1] 3467.88 ± 113.80 3
Fasting insulin [mIU/ml] 16.65 ± 1.18 1
AUC Insulin [mIU/ml x min−1] 46,109.25 ± 3729.84 4
Fasting GIP [pg./ml] 30.15 ± 2.25 3
AUC GIP [pg./ml x min−1] 68,756.03 ± 3585.17 6
Insulin resistance and β cell function:
HOMA-IR 3.88 ± 0.31 4
AUCI/AUCG 13.37 ± 1.07 1
IGI = ΔI0-60/ΔG0-60 186.85 ± 149.60 1
OGIS [ml min−1 m−2] 384.93 ± 9.99 3
1Comparison between placebo and n-3 PUFA groups (unpaired t test or Mann–Whitney U test
2Mean ± SEM (all such values).
3Median; IQR in parentheses (all such values)
AUC, area under curve during OGTT; BP, blood pressure; BMI, body mass index; EPA, eicosapen
tide; IGI, insulinogenic index; NEFA, non esterified fatty acids; OGIS, oral glucose insulin sensitCaloric restriction led to an approximately 8% decrease (p b 0.0001)
of body weight and adipose tissue mass in both groups, without any
statistically significant differences between groups (Table 2). The CR
placebo group showed a 17% decrease in fasting TG concentration as
well as a 16% decrease in TG AUC during OGTT (Table 2). This effect
was greater and more significant in subjects also supplemented with
n-3 PUFA (CR+n-3 group)whose decrease in fasting TG concentration
and TG AUC during OGTT was approximately 30% below baseline (P =
0.0003) (Table 2). Neither caloric restriction nor n-3 PUFA influenced
fastingNEFA or NEFA level duringOGTT (Table 2). No changes in plasma
total, HDL and LDL cholesterol levels were observed after 3 months of
caloric restriction with either placebo (CR placebo) or n-3 PUFA
(CR + n-3) (Table 2).3.3. Changes in the GIP level and insulin sensitivitymarkers after intervention
Three months of caloric restriction alone (CR placebo), or in combi-
nationwith n-3 PUFA (CR+n-3) had no significant affect on the fasting
glucose concentration or glucose AUC during OGTT (Table 2). Caloric re-
striction in combination with n-3 PUFA decreased fasting (Table 2) and
60′ OGTT insulin levels (98.81 ± 10.23 vs. 128.53 ± 14.04 ±IU/ml,
P b 0.05). The insulin OGTT AUC was also significantly decreased
(P b 0.05) (Table 2). These measurements were not affected by caloric
restriction alone. Fasting blood GIP level was lowered in the CR + n-3
group (P b 0.05) (Table 2) and a 30% decrease of the GIP AUC from base-
line was observed (P b 0.01) (Table 2). In contrast, caloric restriction
alone (without n-3 PUFA supplementation) did not affect GIP level at
fasting or during the OGTT (Table 2).lacebo subjects (n = 24) n-3 PUFA subjects (n = 24) P1
8 ± 2 45 ± 2 0.47
0 18
.27 ± 0.28 2.16 ± 0.35 0.82
.72 ± 0.33 3.62 ± 0.27 0.82
.19 ± 0.08 1.05 ± 0.07 0.22
.65 ± 0.22 4.36 ± 0.19 0.32
.85 ± 0.28 5.41 ± 0.25 0.25
7.56 ± 2.12 94.78 ± 2.59 0.41
5.24 ± 0.72 34.25 ± 0.7 0.33
.90 (0.84, 0.95) 0.83 (0.80, 0.91) 0.10
0.7 ± 1.16 38.74 ± 1.33 0.28
32.5 ± 4.08 124.09 ± 2.07 0.09
5.4 ± 2.4 83.14 ± 1.06 0.42
.56 ± 0.28 5.45 ± 0.16 0.72
.38 ± 0.06 1.23 ± 0.04 0.06
.52 ± 0.21 3.53 ± 0.16 0.99
.8 ± 0.05 0.74 ± 0.06 0.48
80.13 ± 16.55 153.05 ± 14.75 0.23
.34 ± 0.13 1.4 ± 0.13 0.77
11.62 ± 58.16 671.87 ± 65.7 0.50
.1 ± 0.13 5.19 ± 0.13 0.62
613 ± 162.58 3322.75 ± 157.03 0.21
7.65 ± 1.94 15.64 ± 1.35 0.40
9,504.75 ± 5704.59 42,713.75 ± 4828.21 0.37
0.88 ± 3.54 29.41 ± 2.86 0.75
7,204.69 ± 5283.18 70,307.36 ± 4940.65 0.67
.11 ± 0.51 3.65 ± 0.34 0.46
3.36 ± 1.46 13.25 ± 1.58 0.96
52.79 ± 270.41 219.43 ± 140.09 0.83
79.66 ± 14.25 390.18 ± 14.21 0.60
for non-normally distributed variables).
taenoic acid; DHA, docosahexaenoic acid; GIP, glucose dependent insulinotropic polypep-
ivity index; PC, phosphatidylcholine; RBC red blood cells.
Table 2
Anthropometric and metabolic variables at baseline and at the end of the study in subjects undergoing caloric restriction and supplemented with placebo or n-3 PUFA capsules.
Placebo (n = 24) n-3 PUFA (n = 24)
Baseline After supplementation P1 Baseline After supplementation P1
Age [y] 48 ± 22 45 ± 2
Sex, female [n] 20 18
EPA in plasmaPC [weight%] 2.27 ± 0.28 1.92 ± 0.21* 0.02 2.16 ± 0.35 3.34 ± 0.54**, # 0.001
DHA in plasma PC [weight%] 3.72 ± 0.33 3.81 ± 0.36 0.62 3.62 ± 0.27 6.47 ± 0.47***, # b0.0001
EPA in RBC membranes [%] 1.19 ± 0.08 1.04 ± 0.08 0.22 1.05 ± 0.07 1.89 ± 0.20***, # 0.0005
DHA in RBC membranes [%] 4.65 ± 0.22 4.49 ± 0.23 0.60 4.36 ± 0.19 7.12 ± 0.19***, # b0.0001
Omega 3 index [%] 5.85 ± 0.28 5.54 ± 0.29 0.44 5.41 ± 0.25 9.01 ± 0.36***, # b0.0001
Anthropometric measurements:
Weight [kg] 97.56 ± 2.12 89.74 ± 2.38*** b0.0001 94.78 ± 2.59 87.93 ± 2.42*** b0.0001
BMI [kg/m2] 35.24 ± 0.72 32.44 ± 0.86*** b0.0001 34.25 ± 0.7 31.66 ± 0.70*** b0.0001
Waist to hip ratio 0.90 (0.84, 0.95)3 0.86 (0.83, 0.91)* 0.03 0.83 (0.80, 0.91) 0.88 (0.80, 0.92) 0.46
Adipose tissue mass [%] 40.7 ± 1.16 37.45 ± 1.46*** 0.0001 38.74 ± 1.33 35.48 ± 1.67*** 0.0004
Metabolic measurements:
Total cholesterol [mmol/l] 5.56 ± 0.28 5.33 ± 0.25 0.28 5.45 ± 0.16 5.20 ± 0.21 0.08
HDL cholesterol [mmol/l] 1.38 ± 0.06 1.42 ± 0.06 0.32 1.23 ± 0.04 1.23 ± 0.04# 0.98
LDL cholesterol [mmol/l] 3.52 ± 0.21 3.34 ± 0.21 0.26 3.53 ± 0.16 3.40 ± 0.18 0.30
Fasting NEFA [mmol/l] 0.8 ± 0.05 0.8 ± 0.07 0.99 0.74 ± 0.06 0.72 ± 0.06 0.83
AUC NEFA [mmol/l x min−1] 180.13 ± 16.55 196.67 ± 19.50 0.33 153.05 ± 14.75 158.35 ± 13.21 0.78
Fasting Triglycerides [mmol/l] 1.34 ± 0.13 1.11 ± 0.09* 0.02 1.4 ± 0.13 0.96 ± 0.07*** 0.0004
AUC Triglycerides [mmol/l x min−1] 611.62 ± 58.16 510.52 ± 40.16* 0.02 671.87 ± 65.7 461.85 ± 40.81*** 0.0003
Fasting glucose [mmol/l] 5.1 ± 0.13 5.16 ± 0.11 0.54 5.19 ± 0.13 5.08 ± 0.07 0.39
AUC Glucose [mmol/l x min−1] 3613 ± 162.58 3468.25 ± 176.61 0.30 3322.75 ± 157.03 3215.5 ± 132.02 0.42
Fasting insulin [mIU/ml] 17.65 ± 1.94 15.32 ± 1.72 0.10 15.64 ± 1.35 12.7 ± 1.02* 0.01
AUC Insulin [mIU/ml x min−1] 49,504.75 ± 5704.59 42,087.39 ± 5595.32 0.12 42,713.75 ± 4828.21 35,725.25 ± 3733.77* 0.04
Fasting GIP [pg./ml] 30.88 ± 3.54 30.36 ± 5.38 0.91 29.41 ± 2.86 20.67 ± 2.24* 0.02
AUC GIP [pg./ml x min−1] 67,204.69 ± 5283.18 74,080.78 ± 8600.00 0.22 70,307.36 ± 4940.65 56,435.58 ± 3743.82** 0.003
Insulin resistance and β cell function:
HOMA-IR 4.11 ± 0.51 3.59 ± 0.43 0.19 3.65 ± 0.34 2.89 ± 0.25* 0.01
AUCI/AUCG 13.36 ± 1.46 11.72 ± 1.25 0.08 13.25 ± 1.58 11.22 ± 1.17* 0.02
IGI = ΔI0-60/ΔG0-60 152.79 ± 270.41 269.49 ± 113.57 0.70 219.43 ± 140.09 354.04 ± 153.33 0.52
OGIS [ml min−1 m−2] 379.66 ± 14.25 383.12 ± 17.65 0.78 390.18 ± 14.21 404.38 ± 13.60 0.30
*Significantly different between baseline and after supplementation within a group (paired t test or Wilcoxon's test for non-normally distributed variables).
#Significantly different between placebo and n-3 PUFA groups after supplementation (unpaired t test) p b 0.05.
1Comparison within a group (paired t test or Wilcoxon's test for non-normally distributed variables).
2Mean ± SEM (all such values).
3Median; IQR in parentheses (all such values).
AUC, area under curve during OGTT; BP, blood pressure; BMI, body mass index; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; GIP, glucose dependent insulinotropic polypep-
tide; IGI, insulinogenic index; NEFA, non esterified fatty acids; OGIS, oral glucose insulin sensitivity index; PC, phosphatidylcholine; RBC red blood cells.
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versely correlated with changes in erythrocyte EPA content
(rho = −0.37; P = 0.009) (Table 3). After 3 months of intervention
fasting plasma GIP level correlated positively with fasting plasma TG
level and TG AUC during OGTT (rho = 0.4; P = 0.004) in the CR + n-
3 group (Table 3).
The ratio of insulin to glucose areas under the curve (AUCI/AUCG)
(which reflects the secretory ability of β cells [29]) was significantly de-
creased in the CR+n-3 group (P=0.02), but not in the group receiving
only calorie restriction (Table 2). The insulinogenic index (IGI = ΔI0-60/
ΔG0-60), which measures first phase insulin secretion, and the oral glu-
cose insulin sensitivity index (OGIS) were not significantly changed in
either group (Table 2).
A significant (P=0.01) decrease (by 20%) in insulin resistancemea-
sured by HOMA-IR index was observed in the CR n-3 group, with no ef-
fect in the CR placebo group (Table 2). After intervention the HOMA-IRTable 3
Spearman rank correlation between changes in variables (Δ) during 3 months of low cal-
orie diet enriched placebo or n-3 PUFA capsules.
rho P1
ΔGIP AUC & ΔEPA RBC −0.37 0.009
Fasting GIP & Fasting TG 0.40 0.004
Fasting GIP & TG AUC 0.41 0.004
Fasting GIP & HOMA-IR 0.29 0.047
1Statistically significant correlations, P b 0.05.
GIP, glucose dependent insulinotropic polypeptide; AUC, area under curve during OGTT;
EPA, eicosapentaenoic acid; RBC, red blood cells; TG, triglycerides.index was positively correlated with fasting plasma GIP level (rho =
0.29; P = 0.04) in the CR n-3 group (Table 3).
4. Discussion
The study confirms that controlled caloric restriction leads to loss of
body weight, fat mass and BMI and shows no additional effect of n-3
PUFA on these measures. The main new findings of the study are that
combining caloric restriction with 1.8 g/day of DHA + EPA (in a ratio
of 5:1) improves insulin sensitivity, which was not seenwith caloric re-
striction alone, and causes a greater lowering of plasma triglyceride con-
centration than seen with caloric restriction alone. The subjects studied
were obese andwithout diabetes butwith slightly elevated fasting plas-
ma insulin level as well as total and LDL cholesterol concentrations. The
finding of improved insulin sensitivity with n-3 PUFA is important since
it suggests an improved metabolic function and a possible lowering of
risk for future cardiometabolic complications. The beneficial metabolic
changes induced by n-3 PUFA in individuals with caloric restriction cor-
related with a lower output of GIP.
It is well known that a decrease in bodyweight in obese personswill
per se influence glucose and lipid metabolism, decreasing the risk for
cardiovascular complications [32]. Similarly, marine n-3 PUFA supple-
mentation is reported as a protective factor against dyslipidemia and
atherosclerosis [15,33–34]. Several studies suggest that DHA/EPA can
contribute to additional weight loss in calorie restricted individuals;
thiswould obviously be amajor health benefit. For example, Thorsdottir
et al. reported a greater decrease in bodyweight after 8 weeks of caloric
restriction combined with 1.3 g/day EPA + DHA in comparison to
12 U. Razny et al. / BBA Clinical 4 (2015) 7–13placebo in obese adults [11]. However, the current study did not observe
any additional effect of 1.8 g/d DHA + EPA supplementation for three
months on weight loss and body adipose tissue content compared
with what was observed with caloric restriction alone. Subjects partici-
pating in the current study did not undertake any specific physical activ-
ity regimen and the diet they used was less restricted in comparison to
that of Thorsdottir et al. [11]. Similarly to the findings of our study,
Munro and Garg observed that 8 week dietary supplementation with
6 g/day of n-3 PUFA improved metabolic profile but did not modify
weight of obese patients on a calorie restricted diet [35].
This study demonstrated that in combinationwith caloric restriction
DHA + EPA supplementation decreases GIP output, improves insulin
sensitivity, and lowers plasma triglyceride level. It is widely reported
that n-3 PUFA at a dose of 3–4 g/day can lower fasting plasma triglycer-
ides by 25 to 50% [36]. The current study demonstrates that calorie re-
stricted obese subjects supplemented with a more moderate dose of
DHA + EPA (1.8 g/day) for 3 months show decreases in plasma fasting
triglycerides comparable with these findings. Furthermore, we found
that n-3 PUFA decrease the triglyceride response seen during an
OGTT. This would suggest an improved clearance of triglycerides from
the circulation, perhaps due to improved insulin sensitivity. However,
we did not observe any effect of n-3 PUFA on total, LDL or HDL choles-
terol concentrations. This finding is in agreement with studies by
Schuchardt et al. who demonstrated an increase in omega-3 index of
more than 4% after 6 months of 1.68 g/day n-3 PUFA which also caused
a significant decrease in plasma triglycerides but not in other risk factors
of atherosclerosis such as total and LDL cholesterol concentrations [37].
Marine fish intake has been documented to be associated with im-
proved glucose homeostasis. For example, Feskens et al. showed that
higher intake of marine fish was associated with lowered relative risk
of impaired glucose tolerance [38]. Other studies showed a negative as-
sociation between fish intake and the risk for type 2 diabetes [39–41].
These effects of fish may be due to n-3 PUFA. However, less favourable
effects on glucose control were sometimes observed in subjects supple-
mented with more than 3 g/day of n-3 PUFA [26,42,43]. Our results
demonstrated that n-3 PUFA did not affect fasting glucose but lowered
fasting insulin and decreased basal insulin resistance index (HOMA-IR),
which suggests a reduction of (mainly) hepatic insulin resistance [44–
45]. It has been reported that three months of a low fat diet enriched
with n-3 PUFA in subjects with metabolic syndrome decreased insulin
resistance and improved insulin signalling in subcutaneous white adi-
pose tissue [46]. Improved insulin sensitivity could be related to a re-
duction of post oral glucose load lipaemia or to anti-inflammatory
effects of n-3 PUFA [47–48]. We did not observe statistically significant
changes in first phase insulin secretion (IGI index) or in empirical index
of insulin sensitivity during OGTT [31].
In our study the combination of 1.8 g/d of n-3 PUFA and calorie re-
striction, but not calorie restriction itself, resulted in a decrease in GIP
concentration in the fasting state and during oral glucose load in
obese patients. DecreasedGIP could contribute to the observed decrease
of β-cell function index measured by post oral glucose load insulin se-
cretion (AUCINS/AUCGLUCOSE). Several studies report thatβ-cell secretion
is sensitive to thedegree of unsaturation of fatty acids [49].We observed
that changes in serumGIP levelswere inversely correlatedwith changes
in erythrocyte EPA and that fasting GIP levels were positively correlated
with insulin resistance index (HOMA-IR). These observations suggest
that n-3 PUFA treatment improves insulin sensitivity by lowering GIP
level. As a consequence of lower GIP signalling, oxidation of fat is
induced, which leads to clearing triglycerides from liver and muscles,
suppression of hepatic glucose output and improvement in insulin sen-
sitivity. Studies in animal models are consistent with this. Flachs et al.
suggested that in mice fed with a high fat diet, supplementation with
DHA + EPA (30 g/kg of diet) could normalize elevated GIP levels and
contribute to an increase in whole body insulin sensitivity [50]. It was
also reported that reduction of GIP secretion, by deletion of the GIP
gene in mice, reduced insulin secretion and lessened the degree ofinsulin resistance with high fat feedingwithout changing glucose levels
during OGTT [51].
Several studies report that plasma GIP is elevated in obesity and
metabolic syndrome [52–53] and in subjects with impaired glucose tol-
erance [54–56]. Interestingly, it was also reported that GIP/GIP receptor
signalling was disrupted in type-2 diabetes and this could contribute to
elevated GIP secretion. Hyperglycemia per se led to down-regulation of
GIP receptor expression. As a consequence, insulin response to GIP was
markedly reduced in islets, which resulted in the deterioration of β-cell
function found in diabetes. Therefore, normalization of GIP/GIP receptor
signalling has been suggested as a potential target in the treatment of
obesity-associated type 2 diabetes [57]. Results of this study also argue
for the suggestion that an inhibition of GIP signalling is beneficial in in-
sulin resistance. In diabetic patientswithβ-cell dysfunction as a result of
lipo- and glucotoxicity, normalizing of GIP/GIP receptor signalling could
improve β-cell function and thus glucose homeostasis.
In vitro studies demonstrated that GIP influences lipid metabolism
in adipocytes from rodents [58] and humans [59]modifying lipogenesis
[60] and lipolysis [61–63]. In turn, studies in vivo showed an association
between plasma fasting GIP and triglycerides' level (fasting and post
oral glucose load) [64]. In this studywe have also observed that after in-
terventionwith calorie restriction, higher fastingGIP levelswere related
to higher fasting and post oral glucose load triglycerides' levels.
5. Conclusions
The current study suggests that providing n-3 PUFA to obese sub-
jects undergoing caloric restriction results in beneficial effects on insulin
sensitivity, which may be related to a decrease of plasma GIP levels.
These findings require confirmation in a larger trial.
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